Department of Chemistry and Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA 30303, United States.
Department of Pediatrics and Aflac Cancer and Blood Disorders Center, Emory University School of Medicine, Atlanta, GA 30322, United States.
Bioorg Med Chem. 2019 Sep 1;27(17):3860-3865. doi: 10.1016/j.bmc.2019.07.019. Epub 2019 Jul 11.
In a previous study, a novel anthraquinone analog BW-AQ-101 was identified as a potent inducer of MDM2 degradation, leading to upregulation of p53 and apoptosis in cell culture studies. In animal models of acute lymphocytic leukemia, treatment with BW-AQ-101 led to complete disease remission. In this study, we systematically investigated the effect of substitution patterns of the core anthraquinone scaffold. Through cytotoxicity evaluation in two leukemia cell lines, the structure-activity relationship of thirty-two analogs has been examined. Several analogs with comparable or improved potency over BW-AQ-101 have been identified. Western-blot assays verified the effect of the potent compounds on the MDM2-p53 axis. The study also suggests new chemical space for further optimization work.
在之前的研究中,一种新型蒽醌类似物 BW-AQ-101 被鉴定为一种有效的 MDM2 降解诱导剂,在细胞培养研究中导致 p53 上调和细胞凋亡。在急性淋巴细胞白血病的动物模型中,BW-AQ-101 的治疗导致完全疾病缓解。在这项研究中,我们系统地研究了核心蒽醌支架取代模式的影响。通过在两种白血病细胞系中的细胞毒性评估,检查了 32 种类似物的结构-活性关系。已经鉴定出几种类似物的活性与 BW-AQ-101 相当或优于 BW-AQ-101。Western-blot 检测验证了有效化合物对 MDM2-p53 轴的作用。该研究还为进一步的优化工作提供了新的化学空间。